DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for peptic ulcer disease — screening already-approved drugs against its 43-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePeptic ulcer disease maps to a 43-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for peptic ulcer disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
activity regulated cytoskeleton associated protein (ARC) — ARC is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet acedrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6TNQ · 1.3 Å · ligand ACETYL GROUP (ACE). Experimental structure, not a prediction.
What the evidence adds up to
Peptic ulcer disease remains one of the most common chronic infections in human populations, particularly in the third world, and can lead to complications including cancers or death. A 2011 book collecting contributions from researchers across Africa, Asia, Europe, North America, and South America covers causes, epidemiology, pathophysiology, molecular-cellular mechanisms, clinical care, and alternative medicine, but offers no new trial data or treatment recommendations.
A 1988 review of recent developments notes that because peptic ulcer disease is multifactorial, the ideal approach would be to use different drugs for different ulcers. Some studies had suggested that subgroups of patients might particularly benefit from specific therapies, but the review critically assessed the available evidence without endorsing any particular regimen.
A 1987 report on current therapy for recurrent ulcer states that the natural history of the disease shows a high rate of recurrence over the short term, with the rate decreasing over many years. Drug therapy does not appear to alter this natural history. Smoking increases the risk of recurrence by accelerating gastric emptying, reducing pancreatic bicarbonate secretion, lowering duodenal luminal pH, decreasing mucosal blood flow, and inhibiting mucosal prostaglandin synthesis. The report finds a probable role for routine maintenance therapy only in patients with known recurrent ulcer disease.
A 2000 study reviewed medical records of 2644 Medicare patients with hospital-discharge diagnoses of peptic ulcer disease in five U.S. states (Colorado, Connecticut, Georgia, Oklahoma, and Virginia). It describes peptic ulcer disease as a common, potentially lethal gastrointestinal disorder and notes dramatic changes in understanding and clinical approach over the prior ten years, but does not report survival, response rates, or specific treatment outcomes from that chart review. What remains missing is any modern randomised trial designed to test a specific repurposed drug against placebo or standard care, with adequate patient stratification by ulcer cause (e.g., H. pylori status, NSAID use) and long-term follow-up for recurrence and complications.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
InTech eBooks · 2011 · 388 citations · open access
Peptic Ulcer Disease
AbstractPeptic ulcer disease is one of the most common chronic infections in human population. Despite centuries of study, it still troubles a lot of people, especially in the third world countries, and it can lead to other more serious complications such as cancers or even to death sometimes. This book is a snapshot of the current view of peptic ulcer disease. It includes 5 sections and 25 chapters contributed by researchers from 15 countries spread out in Africa, Asia, Europe, North America and South America. It covers the causes of the disease, epidemiology, pathophysiology, molecular-cellular mechanisms, clinical care, and alternative medicine. Each chapter provides a unique view. The book is not only for professionals, but also suitable for regular readers at all levels.
Nonoperative Treatment of Perforated Duodenal Ulcer
AbstractOne hundred and six cases of perforated peptic ulcer were treated without operative closure. Only one death occurred due to coronary thrombosis. In addition, four patients died, having been moribund on admission. Treatment consisted of continuous effective gastric decompression, combined intravenous administration of antibiotic and chemotherapeutic agents, sedation and parenteral feeding.
Australian and New Zealand Journal of Medicine · 1975 · 7 citations
Gastric Glycoproteins in Chronic Peptic Ulcer
AbstractThe output and concentration of gastric glycoproteins in gastric juice from patients with chronic duodenal and gastric ulcer and from controls, have been determined in the basal state and following pentagastrin stimulation. Patients with gastric ulcer had a significantly higher basal glycoprotein output, basal glycoprotein concentration and stimulated glycoprotein concentration than patients with duodenal ulcer or controls. The basal and stimulated glycoprotein output in gastric juice from patients with duodenal ulcer and controls was independent of ABO blood group and secretor status. The carbohydrate composition of the gastric glycoproteins has also been determined in the basal state, and following stimulation of gastric juice by pentagastrin, which did not influence the carbohydrate composition of the molecules. The principal carbohydrate components were galactose, N-acetylglucosamine, fucose, N-acetylgalactosamine, and sialic acid. Small amounts of mannose and glucose were detected in some gastric glycoprotein samples. The carbohydrate composition of the glycoproteins varied according to the ABO blood group and secretor status of the individual. Glycoproteins form stimulated gastric juice from non-secretors of groups A and O had a higher sialic acid content than glycoproteins from secretors of the same blood groups. There were no significant differences in the carbohydrate composition of glycoproteins from patients with chronic gastric and duodenal ulcer compared with gastric glycoproteins from control subjects of the same blood group and secretor status.
Scandinavian Journal of Gastroenterology · 1988 · 5 citations
Recent Developments in Peptic Ulcer Treatment
AbstractSince peptic ulcer disease is a multifactorial disease, the ideal therapeutic approach would be to use different drugs for different ulcers. In the past few years some studies have been published suggesting that subgroups of patients with peptic ulcer might particularly benefit from specific forms of therapy. In the present report the available evidence has been critically reviewed.
AbstractPeptic ulcer disease is one of the most common chronic infections in the world. Despite centuries of study, it remains a major digestive disease that affects a lot of people. This book is an update on the latest development in this field. It includes five chapters contributed by scholars from different parts of the world. It discusses the causes, epidemiology, pathophysiology, clinical care, and treatment options for the disease.
Journal of Clinical Gastroenterology · 1987 · 1 citations
Current Therapy for Recurrent Ulcer
AbstractThe natural history of peptic ulcer disease shows a high rate of recurrence over the short term, with the recurrence rate decreasing over a period of many years. Drug therapy does not appear to alter the natural history of the disease. Smoking increases the risk of ulcer recurrence by increasing the rate of gastric emptying, diminishing the secretion of pancreatic bicarbonate, decreasing duodenal luminal pH, reducing mucosal blood flow, and inhibiting mucosal prostaglandin synthesis. There is a probable role for routine maintenance therapy in patients with known recurrent ulcer disease.
AbstractPeptic ulcer disease is a common, potentially lethal, gastrointestinal disorder. Over the last 10 years, there have been dramatic changes in the understanding of and clinical approach to this disorder. Researchers in this study reviewed the medical records of 2644 Medicare patients with hospital-discharge diagnoses of peptic ulcerdisease in 5 U.S. states (Colorado, Connecticut, Georgia, Oklahoma, and Virginia) …
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
